|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 652.16 USD | +0.15% |
|
-4.24% | -15.77% |
| 22/07 | What Bundibugyo Ebola vaccines and treatments are under development | RE |
| 22/07 | Cantor Fitzgerald Adjusts Price Target on Regeneron Pharmaceuticals to $750 From $785 | MT |
| Market Cap | 66.25B 58.27B 54.13B 49.78B 93.36B 6,416B 95.04B 647B 252B 3,129B 249B 243B 10,857B | P/E 2026 * |
17.1x | P/E 2027 * | 13.7x |
|---|---|---|---|---|---|
| Enterprise Value | 58.43B 51.39B 47.74B 43.91B 82.34B 5,658B 83.81B 571B 223B 2,760B 219B 215B 9,575B | EV / Sales 2026 * |
3.68x | EV / Sales 2027 * | 3.16x |
| Free-Float |
72.33% | Yield 2026 * |
0.6% | Yield 2027 * | 0.68% |
Last Transcript: Regeneron Pharmaceuticals, Inc.
| 1 day | +0.16% | ||
| 1 week | -4.24% | ||
| Current month | +4.27% | ||
| 1 month | +5.20% | ||
| 3 months | -15.13% | ||
| 6 months | -13.72% | ||
| Current year | -15.77% |
| 1 week | 637.8 |  | 691.13 |
| 1 month | 619.27 | | 691.13 |
| Current year | 591.52 | | 821.11 |
| 1 year | 541 | | 821.11 |
| 3 years | 476.49 | | 1,211.2 |
| 5 years | 476.49 | | 1,211.2 |
| 10 years | 271.37 | | 1,211.2 |
| Manager | Title | Age | Since |
|---|---|---|---|
| President | 66 | 01/01/2001 | |
| Chief Executive Officer | 73 | 08/01/1988 | |
| Director of Finance/CFO | 55 | 05/02/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 73 | 09/06/2023 | |
Michael Brown
BRD | Director/Board Member | 85 | 01/06/1991 |
Joseph Goldstein
BRD | Director/Board Member | 85 | 01/06/1991 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 2/7/26 | Sell | Director | -200 | 0.0002% | ||
| 1/5/26 | Sell | Director | -100 | 0.0001% | ||
| 1/4/26 | Sell | Director | 100 | 0.0001% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.15% | -4.24% | +13.59% | -10.59% | 66.25B | |
| -0.12% | +3.10% | +40.83% | +196.27% | 52.86B | |
| +0.51% | +37.90% | +37.90% | +37.90% | 43.01B | |
| -1.86% | -4.93% | -56.15% | -56.66% | 39.52B | |
| +1.46% | -3.45% | +54.00% | -27.18% | 29.19B | |
| +0.76% | +0.17% | +65.30% | +84.13% | 23.13B | |
| -1.98% | -10.25% | +63.47% | -53.93% | 23.04B | |
| -1.30% | -6.18% | +3.94% | +177.59% | 20.48B | |
| -1.04% | -1.59% | +66.57% | +124.27% | 16.6B | |
| +0.33% | +3.69% | +80.26% | +150.48% | 16.2B | |
| Average | -0.15% | -1.90% | +36.97% | +62.23% | 33.03B | |
| Weighted average by Cap. | -0.13% | -1.51% | +28.78% | +51.81% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 15.87B 13.96B 12.97B 11.93B 22.37B 1,537B 22.77B 155B 60.49B 750B 59.59B 58.3B 2,601B | 17.61B 15.49B 14.39B 13.23B 24.81B 1,705B 25.26B 172B 67.1B 832B 66.1B 64.67B 2,885B |
| Net income | 3.98B 3.5B 3.25B 2.99B 5.6B 385B 5.7B 38.85B 15.15B 188B 14.93B 14.61B 652B | 5.03B 4.42B 4.11B 3.78B 7.08B 487B 7.21B 49.1B 19.15B 237B 18.87B 18.46B 824B |
| Net Debt | -7.82B -6.88B -6.39B -5.88B -11.02B -758B -11.22B -76.43B -29.81B -370B -29.37B -28.73B -1,282B | -10.51B -9.25B -8.59B -7.9B -14.82B -1,018B -15.08B -103B -40.06B -497B -39.47B -38.61B -1,723B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24/07/26 | USD 650.19 | -0.15% | 708,399 |
| 22/07/26 | USD 651.18 | -3.56% | 872,170 |
| 21/07/26 | USD 675.19 | +0.45% | 529,783 |
| 20/07/26 | USD 672.15 | -0.67% | 624,791 |
| 17/07/26 | USD 676.69 | -0.33% | 648,400 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- REGN Stock
Select your edition
All financial news and data tailored to specific country editions
